title: Pharmacokinetics and tolerance of repeated oral doses of loxiglumide.
abstract: The study was conducted on 6 adult healthy subjects (5 males and 1 female) in order to investigate the pharmacokinetics and tolerance of repeated b.i.d. oral administration for 7 days of tablets containing 400 mg of loxiglumide (CR 1505). The pharmacokinetics of loxiglumide in plasma after the first single dose of 400 mg is characterized by a lag time of 16 +/- 4 min, a rapid invasion (kinv = 10 h-1), a Cmax of 11.9 +/- 5.1 mg/l at tmax of 2.3 +/- 0.8 h, a mean residence time (MRT) of 6.9 +/- 1.1 h and an AUC of 60.6 +/- 16.3 (mg/l) x h. After the last dose of 400 mg the lag time was 17 +/- 6 min, the Cmax 12.7 +/- 3.8 mg/l at tmax of 2.1 +/- 0.8 h, a MRT of 11.0 +/- 1.9 h and an AUC of 109.8 +/- 39.9 (mg/l) x h. The increases of the AUC and of MRT were statistically significant and are probably due to an accumulation of loxiglumide which occurs during the repeated dose course and reaches the steady state within 48 h of repeated administration. Due to this accumulation the Cmax increased by 7%. The increase was not statistically significant or clinically relevant. No dose adjustment seems required during a repeated dose dosing schedule with 400 mg b.i.d. In the urine loxiglumide and 3 metabolites were found, which were called Metabolite (Met.) 11.2, Met. 12.0 and Met. 12.8. Met. 12.0 was the most abundant, accounting for 45% of the loxiglumide related substances excreted in the urine.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Rotta Research Laboratorium, Monza, Italy.
authors.forename: I
authors.initials: I
authors.lastname: Setnikar
authors.forename: R
authors.initials: R
authors.lastname: Chisté
authors.forename: G
authors.initials: G
authors.lastname: Giacovelli
authors.forename: L C
authors.initials: LC
authors.lastname: Rovati
mesh_terms: D000328:Adult; D001711:Biotransformation; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D005260:Female; D005973:Glutamine / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D010349:Patient Compliance; D011377:Proglumide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D005973:Glutamine; C053737:loxiglumide; D002766:Cholecystokinin; D011377:Proglumide